This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Lena Chaihorsky, BS
Advertisement
Articles by Lena Chaihorsky, BS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Judge Denies Preliminary Injunction in Medicaid Work Requirements Case
2
AHRQ Grant Freeze Halts Patient Safety Research Nationwide
3
FDA Advisory Panel Votes Against Approval of Deramiocel for DMD
4
MASLD, MASH Linked to Higher Mild Cognitive Impairment Risk, Lower Dementia Odds
5